Recurrent or Refractory PTCL
Conditions
Brief summary
Phase I portion: To confirm safety and tolerability in recurrent/refractory peripheral T-cell lymphoma patients during repeated oral administration of forodesine 300 mg twice daily (600 mg/day) for 28 days, and determine the recommended dose. Also, to evaluate pharmacokinetics. Phase II portion: To evaluate the efficacy, safety, and pharmacokinetics of the recommended dosage regimen determined in the phase I portion. The primary efficacy endpoint shall be objective response rate (ORR).
Interventions
Sponsors
Mundipharma K.K.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Japanese patients at least 20 years of age. * Patients histologically diagnosed with peripheral T-cell lymphoma by pathological diagnosis of biopsied lesion. In this study, peripheral T-cell lymphoma is defined as the following mature T-cell/NK-cell neoplasms found in the 4th edition of the WHO Classification. * Recurrent/refractory patients with a treatment history of at least one regimen. * Patients with an enlarged lymph node or extranodal mass lesion clearly measurable in two perpendicular directions and greater than 1.5 cm in maximum diameter on computed tomography performed. * Patients expected to survive for at least 3 months. * ECOG PS 0-1. * Patients with adequate hemopoietic efficacy, liver and kidney function. * Patients from whom written consent has been obtained prior to study initiation.
Exclusion criteria
* Patients who received a chemotherapy agent or a high dose of a systemic adrenocorticosteroid within 21 days prior to initial administration of the study drug. * Patients who received radiation therapy, phototherapy, or electron beam therapy within 21 days prior to initial administration of the study drug. * Patients who received another study drug within 28 days prior to initial administration of the study drug. * Patients who received antibody therapy within 100 days prior to initial administration of the study drug. * Patients with a history of allogeneic hematopoietic stem cell transplantation. Or patients with a history of autologous hematopoietic stem cell transplantation within 100 days prior to initial administration of the study drug. * Patients with cerebral metastasis or central nervous system lesion or a past history. * Patients with active multiple primary cancer. Or patients with a history of a malignant neoplasm other than peripheral T-cell lymphoma within the past 5 years. * Patients with severe cardiovascular disease. * Patients with congenital long QT syndrome. * Patients with QTcF \>0.48 sec. * Patients positive for HBs antigen, HCV antibody or HIV antibody on immunological investigation. Or patients positive for either HBc antibody or HBs antibody, and showing DNA more than sensitivity in HBV-DNA assay. * Patients positive for CMV antigen on immunological investigation. * Patients with infectious disease requiring treatment consisting of intravenous administration of antibacterial agent, fungicide, or antiviral drug. * Patients with interstitial pneumonia or pulmonary fibrosis, or patients judged to have insufficient pulmonary function.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate (ORR) based on evaluation by image assessment committee | 2 years |
Countries
Japan
Outcome results
None listed